歯科・口腔外科領域における炎症性疾患に対するエモルファゾンの臨床評価 : アスピリンとの二重盲検比較試験

概要

論文の詳細を見る
Emorfazone, a non-steroidal analgesic and anti-inflammatory drug, was clinicallyevaluated by the double-blind controlled study. The clinical usefulness of Emorfazone on oral inflammatory disease at a daily dose of 600 mg was compared with that of aspirin at a daily dose of 1, 500 mg according to the preliminary study. The results were as follows: 1. Out of the total 192 cases, 186 were needed on safeness study and 178 on usefulness study. 2. The rate of subjective improvement and the efficacy rate judged by the doctor were not significantly different between the drugs at any phases. 3. The frequency of side effects was 11.1%(10 cases) in Emorfazone and 10.4%(10 cases) in aspirin. Almost all cases were accompanied with slight gastrointestinal disorder. 4. The rates of final over-all improvement and usefulness were 67.1%, 62.4% respectively in the E group and 63.7%, 55.9% respectively in the A group. There was no significantdifference between the two drugs. These results suggest that Emorfazone is a useful drug for the treatment of oral inflammatory diseases.